This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Two studies published in Nature found stem cell-derived products can not only be...
The president’s executive order promising to lower pharmaceutical prices include...
The advisory committee, which met Tuesday for the first time since Robert F. Ken...
After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug i...
The biotech is developing an experimental drug for the most common of a family o...
HHS bypassed normal procedures as it laid off thousands of employees, according ...
While J&J expects tariffs will cost it $400 million this year, the company maint...
Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercia...
The Commerce Department has begun a so-called Section 232 investigation into the...
Signs of potential liver damage in a study participant led the company to abando...
The Atlas-backed company plans to liquidate its assets, including an experimenta...
As first quarter earnings begin, executives are confronting market turmoil, regu...
Wall Street analysts said the results for Verve’s therapy appeared competitive o...
Discover how QIAGEN PGXI transforms pharmacogenomics with faster, more accurate ...
With AI, the rich details hidden in unstructured clinical data are now available...
The rare disease drug landscape is evolving, with regulatory guidance shaping it...
The initiative, which will start with monoclonal antibodies, is the first big re...
The bispecific antibody helped people with small cell lung cancer live longer, A...
Novartis expects the new capacity will allow it to produce all of its key medici...
Amid a funding drought for startups, the company is looking for a deal that can ...
Experts say the layoffs are already causing issues in drug development — and thi...
In its first full year on the U.S. market, bladder cancer treatment Adstiladrin ...
Shares in many large drugmakers fell Wednesday on the president's threat, which ...
AdvaMed and other healthcare groups have pleaded for the Trump administration to...